查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945890

疟疾疫苗市场－全球产业规模、份额、趋势、机会及预测（依疫苗类型、给药途径、地区及竞争格局划分，2021-2031年）

Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Route of Administration, By Region and Competition 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球疟疾疫苗市场预计将经历显着成长，预计从 2025 年的 14.1 亿美元成长到 2031 年的 38.4 亿美元，复合年增长率达到 18.17%。

该领域专注于研发和推广旨在赋予人体对疟疾原虫适应性免疫的生物製药。推动该市场发展的关键因素在于降低高流行地区疾病负担的紧迫性，以及国际卫生组织实施的强有力的采购框架。这些结构性基础提供了稳定的需求来源，使其不受瞬息万变的技术趋势影响，从而确保市场扩张植根于可持续的公共卫生策略，而非昙花一现的研究趋势。

市场概览
预测期 2027-2031
市场规模：2025年 14.1亿美元
市场规模：2031年 38.4亿美元
复合年增长率：2026-2031年 18.17%
成长最快的细分市场 多抗原
最大的市场 北美洲

儘管有这些正面迹象，但市场仍面临严峻挑战，产能与全球庞大的需求之间存在巨大缺口，供应链瓶颈也常常阻碍疫苗及时送达偏远地区。根据全球疫苗免疫联盟（Gavi）的数据，2024年，超过1050万剂疟疾疫苗被采购并分发至17个疟疾流行国家。这一数字凸显了扩大生产设施的迫切需求，以及为充分满足当前市场需求而面临的巨大物流压力。

市场驱动因素

将疟疾疫苗纳入国家常规免疫规划是市场成长的关键驱动因素。这将使疫苗接种从有限的试点阶段过渡到全国范围的推广，从而显着扩大覆盖人群。这项转变需要稳健的供应链和政府对持续供应的坚定承诺。正如全球疫苗免疫联盟（Gavi）2025年4月发布的报告《疟疾消除疫苗接种》中所述，已有25个国家的疫苗接种资金获得核准，这表明除最初的试点国家外，疫苗需求将大幅增长。为了支持这项广泛的推广，采购机构正在积极谈判有利的商业条款，以在预算范围内最大限度地扩大覆盖范围。联合国儿童基金会于2025年11月宣布，新的供应协议将节省9,000万美元，从而能够采购数百万剂额外的疫苗。

此外，主要国际组织增加的资金投入和采购承诺为製造商提供了扩大营运规模所需的财务稳定性。与受消费者购买力波动影响的民营市场不同，製药业依赖持续的捐助资金来弥合低收入国家生产成本与消费者承受能力之间的差距。这种财务保障使药物研发者能够投资于长期产能扩张，而无需承担市场风险。例如，全球疫苗免疫联盟（Gavi）于2025年宣布计划在2026年至2030年间向其疟疾疫苗计画投资超过11亿美元，这是一项至关重要的倡议，旨在使生产规模与全球消除疟疾的目标保持一致。

市场挑战

全球疟疾疫苗市场面临的一大限制因素是产能有限与全球迫切需求之间的巨大不匹配。儘管国际需求旺盛，但生产所需的复杂生物製程阻碍了产量的快速成长，无法满足激增的需求。这种不平衡导致潜在收益延迟，而产品供不应求也从根本上限制了疫苗的广泛应用，因此无法显着提升市场价值。

因此，供应链瓶颈和严格的生产限制迫使执行机构只能配给供应，而无法满足全部市场需求。这种无法有效涵盖全部潜在市场（TAM）的情况限制了产业的成长速度。据联合国儿童基金会称，2024年确保的RTS,S疫苗供应量仅为2023-2025年期间的约1800万剂，远低于目标国家的迫切需求。这些限制意味着实际市场规模小于预测模型所显示的规模，成长仍然主要受物流可行性而非购买意愿的驱动。

市场趋势

新一代mRNA疫苗平台的开发代表着一项重要的技术转捩点，它克服了传统蛋白质製剂的疗效限制。研发人员旨在利用这种扩充性的架构来靶向多种疟原虫阶段，从而加速设计迭代并提高疫苗对复杂疟疾原虫的持久性。然而，向这些新型机制的过渡需要经过严格的监管审查，这是实验性生物平台的典型特征，并可能导致间歇性延误。例如，Contagion Live在2025年3月报道称，美国FDA已暂时中止了BioNTech公司mRNA候选疫苗BNT165e的I/II期临床试验。该试验已招募了约180名受试者，凸显了严格监管该技术的安全通讯协定的重要性。

同时，向疫情地区部署生产能力的趋势正在重塑全球供应链，透过在疫情高负担地区附近建立生产网络来实现这一目标。这一结构性趋势旨在减少对跨洲集中式供应链的依赖，并降低成品进口带来的物流风险。国际卫生组织正积极支持区域自主，透过资助基础建设，使非洲国家能够管理自身的卫生安全。正如世界卫生组织（世卫组织）2025年8月的一份报告所强调的，国际药品采购机制（Unitaid）已承诺向一项旗舰项目提供约5000万美元的资金，以加强非洲本地生产基本医疗诊断和治疗产品的能力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球疟疾疫苗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依疫苗类型（红血球前期疫苗、红血球期疫苗、多抗原疫苗、其他）
    • 依给药途径（肌肉注射、皮下注射、皮内注射、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美疟疾疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲疟疾疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区疟疾疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲疟疾疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲疟疾疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球疟疾疫苗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • GlaxoSmithKline, Plc.
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Sanaria Inc.
  • Merck & Co.
  • Johnson & Johnson
  • Pfizer Inc.
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • Moderna Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 14997

The Global Malaria Vaccine Market is projected to experience substantial growth, increasing from USD 1.41 Billion in 2025 to USD 3.84 Billion by 2031, achieving a CAGR of 18.17%. This sector focuses on the creation and distribution of biological preparations aimed at conferring acquired immunity against Plasmodium parasites. The primary forces driving this market are the critical imperative to reduce the disease burden in high-transmission areas and the strong procurement frameworks implemented by international health organizations. These structural pillars provide a consistent demand base independent of fleeting technological trends, ensuring that market expansion is rooted in enduring public health strategies rather than temporary research shifts.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.41 Billion
Market Size 2031USD 3.84 Billion
CAGR 2026-203118.17%
Fastest Growing SegmentMulti-antigen
Largest MarketNorth America

Despite these positive indicators, the market confronts a significant hurdle regarding the disparity between manufacturing capacities and the immense scale of global demand, as supply chain constraints frequently impede the timely delivery of vaccines to remote regions. Data from Gavi, the Vaccine Alliance, indicates that in 2024, over 10.5 million malaria vaccine doses were procured and distributed to 17 endemic nations. This figure highlights the intense logistical pressures and the urgent need for expanded production facilities to adequately serve the requirements of the current market landscape.

Market Driver

The incorporation of malaria vaccines into National Routine Immunization Schedules serves as the primary engine for market growth, transitioning the sector from restricted pilot schemes to broad national adoption. This shift vastly expands the addressable patient population, requiring resilient supply chains and steadfast government dedication to consistent delivery. As noted in Gavi's April 2025 report, 'Rolling out vaccines to beat malaria together,' funding was approved for 25 countries to introduce the vaccine, signaling a rapid surge in demand beyond the initial pilot nations. To support this broad rollout, procurement agencies are actively negotiating beneficial commercial terms to maximize reach within budgetary limits, with UNICEF announcing in November 2025 that a new supply agreement secured US$ 90 million in savings to purchase millions of additional doses.

Furthermore, increased funding and procurement pledges from major international bodies provide the necessary financial stability for manufacturers to scale their operations. Distinct from private markets influenced by variable consumer spending power, this sector depends on sustained donor capital to reconcile the difference between production costs and affordability in low-income nations. These financial assurances enable pharmaceutical developers to invest in long-term capacity expansion without facing unmitigated market risks. For instance, Gavi announced in 2025 a plan to invest over US$ 1.1 billion in malaria vaccination programs during the 2026-2030 period, a commitment essential for aligning manufacturing output with global disease eradication goals.

Market Challenge

A critical constraint on the Global Malaria Vaccine Market is the disconnect between limited manufacturing capabilities and the immediate magnitude of global demand. Although international mandates drive substantial order volumes, the intricate biological processes required for production prevent manufacturers from rapidly increasing output to match this surge in interest. This imbalance creates a scenario where potential revenue is postponed, and the widespread adoption necessary for significant market valuation is physically restricted by product unavailability.

Consequently, supply chain bottlenecks and rigid production ceilings compel implementing organizations to ration distributions rather than fulfilling the total market potential. This inability to effectively service the total addressable market limits the industry's growth rate. According to UNICEF, the secured supply of the RTS,S vaccine in 2024 was restricted to approximately 18 million doses for the 2023-2025 period, a volume far below the immediate needs of eligible nations. Such constraints ensure that the actual market size remains smaller than demand models predict, with growth dictated more by logistical feasibility than by buyer intent.

Market Trends

The development of Next-Generation mRNA Vaccine Platforms marks a significant technological shift aimed at overcoming the efficacy limitations of earlier protein-based formulations. Developers are utilizing this scalable architecture to target multiple parasite stages, aiming to accelerate design iterations and enhance durability against the complex Plasmodium pathogen. However, the move to these novel mechanisms involves rigorous regulatory scrutiny typical for experimental biological platforms, which can lead to intermittent delays. For example, Contagion Live reported in March 2025 that the US FDA paused BioNTech's Phase I/II trial of the mRNA candidate BNT165e, which had enrolled nearly 180 participants, underscoring the strict safety protocols governing this technology.

Simultaneously, the localization of manufacturing capabilities in endemic regions is reshaping the global supply landscape by positioning production closer to high-burden populations. This structural trend seeks to reduce reliance on centralized intercontinental supply chains, thereby mitigating the logistical risks associated with importing finished doses. International health agencies are actively supporting regional autonomy by funding infrastructure that enables African nations to manage their own health security. As highlighted in an August 2025 World Health Organization report, Unitaid pledged nearly US$ 50 million to flagship programs designed to boost Africa's capacity to locally produce essential medical diagnostics and therapeutics.

Key Market Players

  • GlaxoSmithKline, Plc.
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Sanaria Inc.
  • Merck & Co.
  • Johnson & Johnson
  • Pfizer Inc.
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • Moderna Inc

Report Scope

In this report, the Global Malaria Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Vaccine Market, By Vaccine Type

  • Pre-Erythrocytic
  • Erythrocytic
  • Multi-antigen
  • Others

Malaria Vaccine Market, By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Intradermal
  • Others

Malaria Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Vaccine Market.

Available Customizations:

Global Malaria Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others)
    • 5.2.2. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Malaria Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vaccine Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malaria Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vaccine Type
        • 6.3.1.2.2. By Route of Administration
    • 6.3.2. Canada Malaria Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vaccine Type
        • 6.3.2.2.2. By Route of Administration
    • 6.3.3. Mexico Malaria Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vaccine Type
        • 6.3.3.2.2. By Route of Administration

7. Europe Malaria Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vaccine Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malaria Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vaccine Type
        • 7.3.1.2.2. By Route of Administration
    • 7.3.2. France Malaria Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vaccine Type
        • 7.3.2.2.2. By Route of Administration
    • 7.3.3. United Kingdom Malaria Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vaccine Type
        • 7.3.3.2.2. By Route of Administration
    • 7.3.4. Italy Malaria Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vaccine Type
        • 7.3.4.2.2. By Route of Administration
    • 7.3.5. Spain Malaria Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vaccine Type
        • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Malaria Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Malaria Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vaccine Type
        • 8.3.1.2.2. By Route of Administration
    • 8.3.2. India Malaria Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vaccine Type
        • 8.3.2.2.2. By Route of Administration
    • 8.3.3. Japan Malaria Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vaccine Type
        • 8.3.3.2.2. By Route of Administration
    • 8.3.4. South Korea Malaria Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vaccine Type
        • 8.3.4.2.2. By Route of Administration
    • 8.3.5. Australia Malaria Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vaccine Type
        • 8.3.5.2.2. By Route of Administration

9. Middle East & Africa Malaria Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vaccine Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Malaria Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vaccine Type
        • 9.3.1.2.2. By Route of Administration
    • 9.3.2. UAE Malaria Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vaccine Type
        • 9.3.2.2.2. By Route of Administration
    • 9.3.3. South Africa Malaria Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vaccine Type
        • 9.3.3.2.2. By Route of Administration

10. South America Malaria Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vaccine Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vaccine Type
        • 10.3.1.2.2. By Route of Administration
    • 10.3.2. Colombia Malaria Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vaccine Type
        • 10.3.2.2.2. By Route of Administration
    • 10.3.3. Argentina Malaria Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vaccine Type
        • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Malaria Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline, Plc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Takeda Pharmaceutical Company
  • 15.4. Sanaria Inc.
  • 15.5. Merck & Co.
  • 15.6. Johnson & Johnson
  • 15.7. Pfizer Inc.
  • 15.8. Serum Institute of India Private Limited
  • 15.9. Bharat Biotech International Limited
  • 15.10. Moderna Inc

16. Strategic Recommendations

17. About Us & Disclaimer